Fat Loss & Metabolic Peptides

Fat loss and metabolic peptides encompass a spectrum of compounds that target adipose tissue, appetite regulation, and metabolic signalling — from cutting-edge GLP-1 medications to research peptides with decades of preclinical data. This is one of the fastest-evolving areas in both pharmaceutical medicine and peptide research, driven by rising rates of obesity, type 2 diabetes, and metabolic syndrome globally.

Semaglutide and tirzepatide represent the licensed, pharmaceutically approved end of this spectrum. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist that suppresses appetite through hypothalamic signalling, slows gastric emptying, and improves insulin sensitivity. In clinical trials, weekly semaglutide achieved 15-17% body weight reduction over 68 weeks. Tirzepatide (Mounjaro) adds GIP receptor agonism to GLP-1, producing a dual incretin effect that drives up to 22% weight loss in clinical studies — the highest efficacy of any approved anti-obesity medication.

AOD-9604 occupies a different niche within this category. A C-terminal fragment of human growth hormone (hGH176-191), AOD-9604 was developed to isolate the fat-metabolising effects of growth hormone without its growth-promoting or insulin-desensitising properties. Preclinical studies demonstrate direct stimulation of lipolysis in adipocytes and inhibition of lipogenesis. The US FDA granted AOD-9604 GRAS (Generally Recognised As Safe) status for use as a food ingredient, making it one of the few research peptides with formal safety designation.

In the UK, semaglutide and tirzepatide are MHRA-approved prescription medications available through NHS and private providers. NHS prescribing for weight management follows NICE guidelines (TA875, TA943) — patients typically require a BMI of 35+ with weight-related comorbidities for NHS access, though criteria are expanding. AOD-9604 and similar research peptides are unregulated and cannot be marketed as medicines.

Common research questions in this category include: optimising GLP-1 therapy for body composition rather than weight alone; mitigating muscle loss during rapid weight loss; combining appetite suppression with peripheral fat metabolism; and strategies for metabolic flexibility. Some online sources propose pairing licensed GLP-1 medicines with unlicensed peptides such as ipamorelin, CJC-1295, or tesamorelin to "preserve lean mass" — these combinations have no controlled human trial evidence in this context and Peptide Authority does not publish stacking protocols.